BeOne Medicines

#News for #Investors and #Media: We’re expanding our U.S. manufacturing footprint. Today, we're announcing a $300 million expansion of our flagship U.S. manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, New Jersey. The investment adds small molecule manufacturing capacity, brings our total U.S. manufacturing investment to more than $1 billion, creates 120 new jobs, and supports the advancement of our deep oncology pipeline of 35+ clinical and commercial-stage assets. 🔗ir.beonemedicines.com/news/beone-med… #BeOneInnovator #Oncology

#News for #Investors and #Media: Our investigational PRMT5 inhibitor was granted Orphan Drug Designation by the FDA for the treatment of pancreatic cancer. #PancreaticCancer #BeOneInnovator

#TeamBeOne is in Munich this week at #ESMOGI26 to share new data and exchange perspectives on the latest science in GI oncology. The team has gathered to show their support for our message: whether it’s on the field or in our shared purpose against cancer – we believe One Save Changes Everything.

BeOne has been recognized by @usnews as one of the Best Companies to Work For. This recognition affirms our belief that our greatest strength is our people – over 12,000 strong across six continents – united by science, driven by purpose, and relentless in our focus on patients. Learn more: careers.usnews.com/companies/beon… #TeamBeOne #BeOneAgainstCancer #CompanyCulture

#News for #Investors and #Media: BeOne announces positive topline results from the first Phase 3 study evaluating our foundational BTK inhibitor in combination with rituximab versus standard chemoimmunotherapy in previously untreated adult mantle cell lymphoma patients. Read the full announcement: ir.beonemedicines.com/news/beone-med… #Oncology #MCL #BeOneInnovator

At BeOne, we believe no one should face cancer alone. We're honored to announce an expanded, first-of-its-kind partnership with @BloodCancerUtd — a three-year commitment to provide more patients and families with trusted education, personalized support, and community programs that help them navigate every step of the blood cancer journey. Together, we are how the world stops cancer. Learn more: ir.beonemedicines.com/news/blood-can… #BeOneAgainstCancer #PatientsFirst

Cancer is too complex to navigate alone. We’re introducing CLL Navigator™ - a digital hub for trusted education, practical tools, and peer support. Built in partnership with the CLL community, we’re working to empower patients and caregivers with clarity and connection. Learn more: CLLNavigator.com #BeOneVoice

Tack, Stockholm. As #EHA2026 comes to a close, we leave inspired by the scientific momentum shared across the global hematology community. This week reinforced a shared determination to keep pushing innovation forward for patients with blood cancers worldwide. Explore our latest data and congress highlights here: beonemedicines.com/stories/eha-20… #TeamBeOne

At #EHA2026, we're sharing updated data on our BTK degrader in #CLL. Hear from Amit Agarwal, M.D., Ph.D., on the unmet need in CLL and the potential of BTK degradation as a differentiated treatment approach. Learn more about BeOne at EHA: beonemedicines.com/stories/eha-20… #FromFloorToFeed

At #EHA2026, we’re sharing new long- term data in patients aged 80 and older – a population often underrepresented in CLL clinical trials despite the disease predominantly affecting older adults. Hear from Dany Habr, M.D., our Head of Medical Affairs, North America & International Markets, on why these findings matter for clinical practice. Learn more about BeOne at EHA: beonemedicines.com/stories/eha-20… #FromFloorToFeed

#News for #Investors and #Media: This weekend at #EHA2026, we’re presenting updated data evaluating our BTK degrader in patients with CLL/SLL. This data adds to growing research behind next-generation approaches in B- cell malignancies, where resistance and relapse remain ongoing challenges. Explore the data here: ir.beonemedicines.com/news/beone-med… #BeOneInnovator

#News for #Investors and #Media: At #EHA2026, we’re sharing new Phase 3 data in CLL/SLL in patients aged 80 and above to help deepen understanding of a population often underrepresented in clinical research. Explore the data here: ir.beonemedicines.com/news/beone-sho… #BeOneInnovator

@CllSociety spotlighted new results from our ongoing Phase 1/1b study evaluating the combination of our BTK inhibitor and BCL2 inhibitor in treatment-naïve CLL/SLL. Dive deeper into these data and their implications for patients living with CLL/SLL: cllsociety.org/2026/05/sonrot… #CLL #SLL #BeOneAgainstCancer

Three days until #EHA2026. This year, we’re presenting 37 abstracts across hematological cancers, and looking forward to showcasing our findings and shaping where the field goes next. Stay tuned for more. #TeamBeOne #BeOneAgainstCancer

CLL treatment has advanced — but patient access hasn’t kept pace. That’s why we are working with @News_CRA and key partners to release a first-of-its-kind report, 𝙒𝙝𝙚𝙣 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 𝙊𝙪𝙩𝙥𝙖𝙘𝙚𝙨 𝘼𝙘𝙘𝙚𝙨𝙨: 𝘾𝙡𝙤𝙨𝙞𝙣𝙜 𝙩𝙝𝙚 𝙂𝙖𝙥 𝙞𝙣 𝘾𝙇𝙇 𝘾𝙖𝙧𝙚, that explores barriers across the U.S. CLL care journey — from biomarker testing delays to insurance challenges — and the need for more coordinated, patient-centered solutions. Read more: #CLL" target="_blank" rel="nofollow noopener">beonemedicines.com/patients/our-c… #CLL #BeOneAgainstCancer #ASCO

At #ASCO26, we're highlighting long-term data in CLL. 78-months of follow-up from a Phase 3 study provides important insight into the importance of durable outcomes. Hear from Amit Agarwal, M.D., Ph.D. on why these data matter just as much as initial response in CLL. Learn more: beonemedicines.com/stories/asco-2… #FromFloorToFeed #BeOneAtASCO #TeamBeOne

#News for #Investors and #Media: With oral presentations in hepatocellular, gastroesophageal adenocarcinoma and gynecological cancers, our data reflects our focused approach to advancing innovative therapies with speed and purpose, shaping the next generation of options for people living with cancer. Learn more: ir.beonemedicines.com/news/beone-med… #BeOneAtASCO #BreastCancer #LiverCancer #ASCO26